The efficacy and safety of biosimilar infliximab CT-P13 in IBD: a prospective, nationwide, observational cohort (Biosimilar infliximab in IBD)

First published: 21/03/2015

Last updated: 21/03/2015

Study   Ongoing

Administrative details

EU PAS number

EUPAS9053

Study ID

9054

DARWIN EU® study

No

Study countries

Hungary

Study description

Biosimilars are biologic medicines that enter the market subsequent to an original reference product whose patent has expired. Biosimilar infliximab CT-P13 received EMA approval in 2013 and was granted marketing authorization for all of the indications of the reference product, based on parallel-group clinical trials in rheumatoid arthritis (RA) and ankylosing spondylitis. Therefore, inflammatory bowel diseases (IBD) are considered as extrapolated indications. Concerns have been expressed regarding extrapolated indications. The dosing is different in RA (3 mg/kg b.w.) and in rheumatologic diseases combination therapy is more frequently used, which may influence immunogenicity. As of May, 2014 the Hungarian National Health Fund only reimburses the biosimilar infliximab for new induction treatment in IBD. New induction is defined as no infliximab treatment in the previous 12 month, switch was not allowed. Data on the safety and efficacy of biosimilar infliximab in clinical practice in IBD is limited so far. Therefore, the aim of the present study was to conduct a prospective, nationwide, multicentre, observational cohort to examine the efficacy and safety of CT-P13 infliximab biosimilar in the induction and maintenance treatment of Crohn's disease and ulcerative colitis. The primary endpoint of the study was early clinical remission at week 14. Secondary endpoints include early clinical response at week 14, steroid-free clinical remission at week 30, sustained clinical remission and response at week 54, early and sustained biochemical response at week 14 and week 54, mucosal healing at week 54 and safety. Consecutive IBD patients starting on infliximab biosimilar were prospectively enrolled and a standardized monitoring strategy was applied. Demographic data, medication history, clinical, laboratory and endoscopic/radiological imaging were collected. Infliximab trough and anti-drug antibodies were measured at regular intervals. Adverse events were registered.

Study status

Ongoing

Research institutions and networks

Institutions

Semmelweis University

☐ Hungary

First published: 01/02/2024

Last updated: 01/02/2024

Institution **Hospital/Clinic/Other health care facility**

First Department of Internal Medicine

First Department of Internal Medicine, University of Szeged Szeged, Military Hospital – State Health Centre Budapest, First Department of Medicine, Peterfy Hospital, Budapest, Second Department of Medicine, Zala County Hospital Zalaegerszeg, Second Department of Medicine, B-A-Z County and University Teaching Hospital Miskolc, Department of Internal Medicine, Csolnoky Ferenc Regional Hospital Veszprem, Second Departement of Internal Medicine, Semmelweis University

Budapest, Clinical Center Institute of Medicine, Department of Gastroenterology Debrecen, Department of Medicine and Gastroenterology, Markusovszky Hospital Szombathely, Department of Gastroenterology, Tolna County Teaching Hospital Szekszárd

Networks

Hungarian IBD Study Group

Contact details

Study institution contact

Krisztina Gecse krisztina.gecse@gmail.com

Study contact

krisztina.gecse@gmail.com

Primary lead investigator

Krisztina Gecse

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 15/04/2014

Actual: 15/04/2014

Study start date

Planned: 01/05/2014

Actual: 12/05/2014

Date of final study report

Planned: 31/12/2016

Sources of funding

- Pharmaceutical company and other private sector

- Other

More details on funding

Kéry Pharma, National Health Fund

Regulatory

Was the study required by a regulatory body?

No

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Effectiveness study (incl. comparative)

Main study objective:

Data on the safety and efficacy of biosimilar infliximab in clinical practice in IBD is limited so far. Therefore the aim of the present study is to conduct a prospective, nationwide, multicentre, observational cohort to examine the efficacy and safety of CT-P13 infliximab biosimilar in the induction and maintenance treatment of Crohn's disease and ulcerative colitis.

Study Design

Non-interventional study design

Other

Non-interventional study design, other

Intensive monitoring schemes

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

INFLIXIMAB

Medical condition to be studied

Crohn's disease

Colitis ulcerative

Population studied

Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

150

Study design details

Outcomes

The primary outcome of the study is early clinical remission at week 14. Clinical remission in CD was defined as a CDAI of less than 150 points or no fistula drainage according to the fistula drainage assessment. Clinical remission in UC was defined as a partial Mayo score of less than 3 points. Secondary outcomes include early clinical response at week 14, steroid-free clinical remission at week 30, sustained clinical remission and response at week 54, early and sustained biochemical response at week 14 and week 54, mucosal healing at week 54 and safety. Clinical response in CD was defined as a CDAI decrease >70 points or ≥50% reduction in the number of draining fistulas.

Data analysis plan

Data appraisal and statistical analysis will be performed using the SPSS 20.0 software package. Statistical tests include calculating tests of normality, T and

D tests, Chi2 test, Chi2 test with Yates' continuity correction and logistic regression.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Other

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No